IndieBio is the world’s first accelerator devoted to startups using biology to solve the world's largest problems. IndieBio is an SOSV program. SOSV is a global venture capital firm that operates startup accelerator investment programs. At the close of 2020, SOSV had more than 1,000 portfolio companies and $855 million in assets under management.

IndieBio

Expert DOJO is one of the most active international early-stage startup accelerator and venture capital fund in Southern California. We invest on average $50,000 in each of our startups and up to $1,000,000 of follow-on investment to companies who have demonstrated exceptional growth.   We help our companies get traction and scale faster than they could ever do by themselves. Since 2018, we have invested in over 260 startups globally to accelerate their growth. What makes us special is our focus on building visionary companies. If you can visualize your unicorn, you have a higher probability of achieving its full potential. That’s where Expert DOJO comes in. We invest in pre-seed and seed companies ready to scale quickly. Most of our startups are minority and female founded technology companies. However, we remain industry agnostic and invest in founders from all over the world and from diverse backgrounds.

EXPERT DOJO

Stemtech LLC

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins the later rounds of HAX and IndieBio graduates.  HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

SOSV

Newchip is a global remote startup accelerator. Newchip Accelerator, 1401 Lavaca St. PMB 40433, Austin, TX, 78701, Email: investing@newchip.com

Newchip Accelerator

Jointechlabs, Inc.

Jointechlabs is an emerging world leader in point-of-care regenerative medicine therapies with its headquarters in Brandon, FL (outside Tampa). Current products include MiniTC® (for USA) and Mini-Stem System® (for Ex-USA) - medical devices that allow processing of autologous (your own) body fat for use in non-surgical orthopedic and aesthetic procedures in your doctor’s office, providing safe, time efficient, and superior results.  Pipeline products include biologic drugs and 3D Bioprinted products to further expand use in orthopedic, wound healing and plastic and reconstructive surgery . For more information, please visit: https://jointechlabs.com/.

Jointechlabs, Inc. is a pioneering company in the field of regenerative medicine solutions. Its flagship product, MiniTC, is an FDA-cleared device designed to process autologous fat into microfat, a regenerative-cell-rich substance. This microfat can be utilized for various applications, including orthopedic, aesthetic, wound healing, and reconstructive surgery procedures. The company's technology enables healthcare practitioners to provide safe, cost-effective, non-surgical regenerative therapies at the point-of-care without infrastructure changes.

Jointechlabs Enters China Regenerative Medicine Market with Joint Venture and Patent Grant

Jointechlabs Makes Microfat-based Regenerative Medical Procedures More Efficient and Profitable

Jointechlabs launches European expansion with new partnerships, grants, and subsidiary

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

Jointechlabs, Inc. is a pioneering company in the field of regenerative medicine solutions. Its flagship product, MiniTC, is an FDA-cleared device designed to process autologous fat into microfat, a regenerative-cell-rich substance. This microfat can be utilized for various applications, including orthopedic, aesthetic, wound healing, and reconstructive surgery procedures. The company's technology enables healthcare practitioners to provide safe, cost-effective, non-surgical regenerative therapies at the point-of-care without infrastructure changes.
Jointechlabs' unique microfat processing system offers technological superiority, industry-leading microfat purity, quantity, and speed. In September 2023, the company optimized the components and process of MiniTC, streamlining the three phases of microfat-based procedures: fat harvesting, processing, and injection. These optimizations resulted in over 35% efficiency improvements, enhancing patient and physician satisfaction while increasing profitability.
Additionally, Jointechlabs has a robust intellectual property portfolio, including a core Chinese patent (CN115722351A) granted in October 2023, covering the core operations and features of MiniTC. This patent strengthens the company's global intellectual property holdings and facilitates the introduction of its innovations to the Chinese market.
In October 2023, Jointechlabs entered the Chinese regenerative medicine market through a joint venture with Bangyi Medical Technology Co., Ltd., forming Zann Medical Technology Co., Ltd. This partnership aims to market, sell, train, service, and support Jointechlabs' licensed products in China, leveraging Bangyi's extensive distribution network.

3D Bioprinting Solutions is a Russian biotechnology research laboratory focused on developing and commercializing bioprinting technologies. The company was founded by INVITRO, the largest private medical company in Russia, and officially opened its 3D Bioprinting Solutions laboratory in September 2013. Its core activities involve the development and production of bioprinters, bioinks, and biofabrication technologies for regenerative medicine and drug discovery applications.
One of the company's key products is the FABION bioprinter, capable of bioprinting without the need for organic or artificial scaffolds using a proprietary nanotechnology approach. In 2016, 3D Bioprinting Solutions launched the FABION 2, an advanced bioprinter that can print complex structures using tissue spheroids and a wide range of hydrogels with different polymerization mechanisms. The FABION two features a unique laser positioning system with an accuracy of five micrometers, enabling the printing of highly intricate structures.
In 2018, the company delivered its Organ.Aut magnetic 3D bioprinter to the International Space Station (ISS) for conducting experiments in microgravity conditions. The Organ.Aut successfully bioprinted a mouse's thyroid gland in space in December 2018, marking the first instance of living tissue being printed in outer space. In August 2019, the company bioprinted bone tissue aboard the ISS using the Organ.Aut.
3D Bioprinting Solutions has actively pursued collaborations with research institutions and commercial entities worldwide. In April 2019, the company announced plans to collaborate with laboratories from the US and Israel to deliver muscular tissue biomaterials to the ISS for bioprinting experiments using the Organ.Aut bioprinter.

3D Bioprinting Solutions

A.D.A.M. Bioprinting is a company developing an on-demand 3D bioprinting platform for manufacturing personalized implants. Their core technology, a Medical Device Production System, enables medical professionals to complete the entire process of 3D modeling, printing, and sterilization to create customized implants ready for implantation.
The company's initial focus is on producing orthopaedic bone implants for cranial, maxillofacial, general trauma, and orthopaedic oncology surgeries. However, A.D.A.M. Bioprinting plans to expand its offerings to include printed soft tissues in the future.
Founded in 2018, A.D.A.M. Bioprinting has its roots in Ukrainian aerospace and biotech engineering. The company operates with a research and development office in Ukraine, while its US-based entity holds intellectual property and handles business development and marketing functions.
In May 2022, A.D.A.M. Bioprinting was accepted into Elementa Labs, the virtual incubator program of the Mount Sinai Health System in New York. This program aims to optimize, expand, and advance the company's core technology platform, potentially leading to its commercialization in the US market.

A.D.A.M.

Advanced BioMatrix, a San Diego-based biotechnology company, develops advanced biomaterials and reagents for 3D cell culture applications, including cell cultivation, cell assays, bioprinting, and cell proliferation. The company's products have been utilized in groundbreaking research for drug development and 3D bioprinted tissue models, with over 5,000 citations in scientific publications as of September 2021. Advanced BioMatrix's offerings include hydrogels that mimic the extracellular matrix, facilitating cellular attachment, survival, and compatibility with various tissue types.
In September 2021, Advanced BioMatrix was acquired by BICO Group AB, a Swedish bioconvergence company focused on enhancing biology research, for approximately USD 15 million. Following the acquisition, Advanced BioMatrix became a subsidiary of CELLINK Bioprinting, operating under the BICO Group. The company generated approximately USD 3 million in revenue with an adjusted EBITDA margin of around 50% in its latest fiscal year prior to the acquisition.
Key customers and partnerships
Advanced BioMatrix has established collaborations with research institutes, pharmaceutical companies, and life science organizations worldwide. In June 2022, the company expanded its existing partnership with Lineage Cell Therapeutics for Lineage's HyStem cell/drug delivery technology, broadening its focus on manufacturing and supplying research-grade HyStem to the research community and developing clinical/commercial-grade material for Lineage's customers.
In August 2023, Advanced BioMatrix signed a distribution agreement with InSphero AG, a pioneer in 3D cell culture and organ-on-chip technology, to make InSphero's patented Akura Plate Technology available to researchers in the US market. This collaboration aims to expand the application range for scientists and drug developers by combining Advanced BioMatrix's biomaterials with InSphero's Akura Plates for scaffold-based organoid and spheroid cultures.

Advanced Biomatrix

Advanced Solutions Life Sciences, a wholly-owned subsidiary of Advanced Solutions, Inc., is a global leader in 3D biofabrication, headquartered in Louisville, Kentucky. The company pioneered the BioAssemblyBot, the world's first 6-axis robotic human tissue printer capable of systematically reproducing organoids. Their patented 3D printed blood vessel technology, derived from human fat tissue, empowers customers to advance the science of 3D organ printing. Advanced Solutions Life Sciences offers expertise in regenerative medicine, bioinks, 3D tissue assays for drug discovery and testing, 3D tissue modeling, and 3D printing services.
In May 2018, the company expanded its operations by opening a second biofabrication facility and laboratory in Manchester, New Hampshire. This strategic expansion aimed to contribute to curative organ printing solutions and establish the company as a prominent corporate citizen in Manchester.
In January 2023, Advanced Solutions Life Sciences partnered with Molecular Devices, a bioscience company, to develop 3D biology automation solutions. They jointly developed the BioAssemblyBot 400 (BAB 400) for Drug Discovery, integrating Advanced Solutions' bioprinting platform with Molecular Devices' ImageXpress Cellular Imaging System. This automated platform enables consistent, large-scale production of organoid models, enhancing drug discovery research.

Advanced Solutions Life Sciences

Allegro 3D is a bioprinting company specializing in high-throughput and high-precision 3D printing technology for fabricating tissue models at an industrial scale. The company was acquired by BICO, a Swedish bioconvergence company, in May 2022 for an upfront enterprise value of USD 6 million. Allegro 3D's patented light-based digital light processing (DLP) bioprinting technology enables direct printing into multi-well plates, allowing customers to significantly increase their output of biofabricated constructs for applications in regenerative medicine and drug discovery workflows. The company's flagship product, the STEMAKER Model D, utilizes extrusion-based bioprinting to produce bio/organic parts using liquid feedstock. As of 2022, Allegro 3D was expected to generate approximately USD 1 million in revenue with positive EBITDA margins. The acquisition complements BICO's existing portfolio of bioprinters and strengthens its position as a global leader in providing bioprinting solutions.

Allegro 3D

Developing and selling bioprinter devices that can be used by hospitals, research institutes, and other organizations seeking to print biological substitutes and materials.

Companies that use propietary or third-party printers to produce and sell bioprinted tissues, including impants, organ replacement, and other types of tissues.

Companies that are developing materials and bioinks, that can be used in bioprinting devices. This includes material technologies and nanofibers.

Developing software solutions and applications for designing and managing the bioprinting production process.

3D printing enables bioprinting devices, which rely on a similar design and operating model

Startups in this hub are able to customize the bioprinted models to suit each patient

AI/ML is used in the design and optimization of 3D models that can be bioprinted

Jointechlabs, Inc.

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless